Track topics on Twitter Track topics that are important to you
SAN DIEGO, July 22, 2015 (GLOBE NEWSWIRE) -- ICON Vapor, Inc. (OTCQB:ICNV) is pleased to announce that the company is on track with the expansion of distribution and will show significant growth in gross revenue through quarter 2.
ICON Vapor’s CEO, Dan Balsiger, stated, “All our Quarter 2 filings will be issued on time and we are looking forward to sharing our revenue growth with our shareholders. Our sales team has been working extremely hard at moving product into distribution and with this continued development we look forward to positively affecting our financials as we proceed through this fiscal year."
Dan went on to say, “We are also working on and launching two new product categories that are showing incredible growth in the C-store space and are working diligently at moving these product categories into our distribution channels."
ICON Vapor’s CEO stated further, “The successful launch of these two categories in conjunction with the continued development of our Vapor offerings should put us in a position to see a significant increase in both sales volume as well as profitability as we progress through quarter three and four of 2015.”
About ICON Vapor, Inc.:
Headquartered in San Diego, California, ICON Vapor, Inc. engages in the manufacture and distribution of Ultra Premium Vapor Products. The company offers a wide variety of Vapor Products, Vape Pens & E-Liquids that are made in the USA, all branded under the ICON Vapor Products line. For further information please contact the Company at: firstname.lastname@example.org.
Safe Harbor Statement:
This press release may contain forward looking statements and or observations which are based on current expectations, forecasts, and assumptions that involve risks as well as uncertainties that could cause actual outcomes and results to differ materially from those anticipated or expected, including statements related to the amount and timing of expected revenues as well as any payment of dividends on our stock, statements related to our financial performance, expected income, distributions, and future growth for upcoming quarterly and annual periods. These risks and uncertainties include but not limited to information as contained within the Company’s most current quarterly reports, annual reports, and or other such filings as may be accessed through the OTC website. Furthermore, the Company disclaims any intention or obligation to update or revise any such forward looking statements, whether as a result of new information, future events, or otherwise. We have incurred and will continue to incur significant expenses in our expansion of our existing as well as new product lines noting there is no assurance that we will generate enough revenues to offset those costs. Additional product offerings may expose us to additional legal and regulatory costs and unknown exposure(s) based upon the variables as associated with the general business channel we are operating in, the impact of which cannot be predicted at this time including risks as associated with our product and recent FDA pronouncements.
Investor Contact Information: email@example.com 858.564.9513NEXT ARTICLE
The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...